Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome (Mito-LUTS)

Mito-LUTS: A Pilot Study of the Effect of MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

The goal of this clinical trial is to test the effect of a supplement called MitoQ (mitoquinol mesylate) on bladder symptoms such as urgency and frequency in women 50 years and older who have the metabolic syndrome. The main questions it aims to answer are:

• Is the study design feasible and acceptable to participants?
• Do participants taking the study drug get any improvement to their bladder symptoms compared to participants taking a placebo (a look-alike substance that contains no drug)?

Participants will take 2 capsules of the study drug every morning for 4 months, answer many questions about their health including questions about their bladder health, perform physical and cognitive testing, give blood and urine samples, collect urine over 24 hour periods 3 times over the 4 months of the study (optional), complete 3 day bladder diaries about how much they drink and void, undergo electrocardiograms, have their vitals and measurements (weight, height, waist circumference) taken, participate in 4 visits to the clinical research area and participate in many phone calls of varying length. Researchers will compare participants who were taking capsules containing MitoQ and participants taking capsules not containing MitoQ to see if MitoQ improves their bladder symptoms (urgency, frequency, nocturia, incontinence, etc.)

Study Overview

• Status: Terminated
• Conditions: Lower Urinary Tract Symptoms; Overactive Bladder Syndrome
• Intervention / Treatment: Other: Placebo; Drug: MitoQ (mitoquinol mesylate)

Detailed Description

Both aging and the metabolic syndrome are risk factors for lower urinary tract symptoms (LUTS, including urgency, frequency, nocturia (nighttime urination), and incontinence). This study aims to test whether an oral supplement that targets biological aging pathways can improve lower urinary tract symptoms (LUTS) in women aged 50 years and older with the metabolic syndrome (a cluster of conditions that occur together, increasing the risk of heart disease, stroke and type 2 diabetes). MitoQ, a strong mitochondrial-targeted antioxidant molecule, has been shown to target mitochondrial dysfunction, oxidative stress, inflammation, and endothelial dysfunction, all aging pathways that are also found to be dysregulated in conditions that cause LUTS such as the overactive bladder syndrome. Women aged 50 years and older who have the metabolic syndrome per the new International Diabetes Federation (IDF) definition and have had urinary urgency for at least 3 months will be invited to participate in the study. They will be screened by phone for major study inclusion/exclusion criteria and then invited for an in-person screening visit where blood will be drawn and measurements taken to confirm eligibility. Once eligible, participants will be randomly assigned to MitoQ or placebo (2MitoQ:1placebo) and asked to take 2 capsules daily (40mg MitoQ total) 30 minutes before breakfast for 4 months. Participants will come back for study visits at 8 and 16 weeks, and will receive two study data collection phone calls at 4 and 12 weeks, where they will answer questions about their bladder. There will be many other shorter phone calls throughout the study to check for adherence and adverse events. In addition to questionnaires assessing bladder function, participants will undergo tests of frailty, physical function, cognitive function and asked many questions about their health and medication. We will also draw blood for safety assessment and to measure aging molecules in the blood at each visit and see whether they change with treatment. Urine will also be collected at each study visit and participants will be asked to collect urine at home (first morning and 24-hour urine) and bring it to each of their study visits, which will be used for measuring aging molecules and testing how they change with the study drug. Participants will also fill out three-day voiding diaries to provide information about their voiding and LUTS.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Connecticut
    • Farmington, Connecticut, United States, 06030
      • UConn Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

The new IDF's 2006 consensus worldwide definition for MetS will be followed for inclusion. MetS will be defined as having central obesity with ethnicity-specific values, plus two or more of the following criteria: Hypertension, dyslipidemia, or hyperglycemia. Hypertension is defined by the use of antihypertensive medication and/or blood pressure of ≥130/85 mmHg. Dyslipidemia is defined as blood triglycerides >150mg/dL or high-density lipoprotein (HDL) < 50mg/dL, or specific treatment for either lipid abnormality. Hyperglycemia is defined as a fasting glucose ≥100mg/dL. Inclusion criteria for LUTS are having urgency with or without other urinary symptoms for at least 3 months, with a score of 1 or 2 on the Urgency Perception Scale questionnaire 60 , and a total score of at least 6 on the OABSS questionnaire (with at least a score of 2 on the third OABSS question "How often do you have a sudden desire to urinate, which is difficult to defer?").

• Women 50years or older with metabolic syndrome and LUTS as defined above.
• Speak, read and understand English
• Willingness to provide consent and participate in all aspects of the trial including randomization to the intervention group

Exclusion Criteria

The exclusion criteria for Mito-LUTS include conditions that will interfere with our research questions, including advanced co-morbidities and immunological disorders. They are as follows:

• Frailty, defined as meeting 3 of 5 frailty indicators of the Fried Frailty Phenotype
• History of severe renal impairment and/or eGFR ≤ 60 mL/min/1.73m2 at the study physician's discretion
• Excessive alcohol use (more than 14 alcoholic drinks/week)
• Clinical/laboratory evidence of hepatic disease (via medical history and/or AST and/or ALT ≥ 3 times upper limit of normal at screening)
• Poorly Controlled Diabetes
• Unwilling or unable (due to significant cognitive impairment) to provide informed consent.
• Terminal illness with life expectancy less than 12 months
• Advanced neurological disorder (Alzheimer's, Parkinson's, ALS, MS, dementia, seizures)
• A score of 30 or less on the modified Telephone Screening of Cognitive Status administered during the in-person screening visit.
• Cancer or history of gynecological cancer or history of cancer requiring chemotherapy or radiation at the study physician's discretion.
• A history of gastric ulcers.
• Abnormal findings on endoscopy.
• Recent (within the last 2 weeks) or current chronic use of NSAIDs or other drugs or agents with the potential for gastric mucosal toxicity (except for daily use of baby aspirin or famotidine for which participants will not be excluded). Sporadic use of NSAIDs will not be an exclusion criterion.
• Significant co-morbid disease (severe chronic obstructive pulmonary disease, active rheumatologic diseases, chronic infection (HIV, tuberculosis), severe congestive heart failure (NYHA class 4), myocarditis, etc)
• Myocardial infarction, stroke or hospitalization for heart failure in the last 12 months
• QTc >460 ms at screening on ECG
• Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
• Severe active psychiatric disorder (e.g. bipolar, schizophrenia)
• Unable to complete physical performance testing due to medical conditions (at discretion of the PI)
• Unintentional weight loss >15 lbs in past 12 months
• Immunosuppressive disorders or taking immunosuppressive medications (including oral prednisone > 10mg/day)
• Sub-cerebellar lesions
• Subjects must not be on warfarin or other blood thinning medications or have a known bleeding disorder.
• Conditions that might interfere with clinical diagnosis (such as pelvic organ prolapse ≥ stage 2, pelvic radiotherapy, any concurrent condition that could cause incontinence, hematuria, vaginitis, neurogenic lower urinary tract dysfunction); chronic pelvic pain syndrome, interstitial cystitis/bladder pain syndrome, pelvic malignancy, active urinary tract infection (UTI), recent urologic procedure (<6 months).
• Clean intermittent catheterization or indwelling catheter
• Current participation in another interventional study
• Pregnancy and nursing
• Subjects must not have used antibiotics for at least 3 weeks prior to visit 1, received a vaccination in the 2 weeks prior to visit 1 or used medicine that alters the immune response (eg high dose corticosteroids) in the 6 months prior to visit 1. Subjects must not have had an acute infection in the 3 weeks prior to visit 1 or had a major severe illness or been hospitalized in the 3 months prior to visit 1. If participants are within any of these windows when they are screened, they will be scheduled for a screening visit but will only be invited for Visit 1 after these specified windows have elapsed and/or infections have resolved.
• Subjects must not be on or have taken any of the following anti-muscarinics or β3- adrenoreceptor agonists for 3 weeks prior to visit 1: o Darifenacin (enablex), Oxybutynin (ditropan), Solifenacin (vesicare), Fesoterodine (Toviaz), Tolterodine (detrol), Trospium (sanctura), Imipramine (tofranil), Mirabegron (myrbetriq), Vibegron (gemtesa)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo Control group; 2 placebo capsules taken orally daily before breakfast for 4 months	Other: Placebo; Control capsules that contain all inactive ingredients found in the study drug capsules (i.e., placebo capsules do not contain mitoquinol mesylate)
Experimental: MitoQ group; 2x20mg MitoQ (mitoquinol mesylate) capsules taken orally daily before breakfast for 4 months	Drug: MitoQ (mitoquinol mesylate); MitoQ is an antioxidant molecule designed to target cell stress; Other Names: MitoQ

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overactive Bladder Symptom Score (OABSS)	The OBSS is a validated bladder symptom questionnaire routinely used in assessing lower urinary tract symptoms and overactive bladder syndrome. The OABSS questionnaire consists of 4 questions and has a minimum score of 0 and a maximum score of 15. Scores on the OABSS of ≤5 are defined as mild, those of 6-11 as moderate, and those of ≥12 as severe LUTS.	From enrollment to the end of treatment at Week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Three-day bladder voiding diary	Participants will record times and amounts of liquids ingested and urine produced for 3 days. They will also record their urge at each voiding instance and incontinence episodes. Voiding diary measures, including number of voids during the day, number of voids during the night, number of urgency episodes and number of incontinence episodes will all be compared.	From Baseline Visit (Week 0) to end of treatment at Week 16

Collaborators and Investigators

• Sponsor: Iman Al-Naggar, PhD
• Collaborators: National Institute on Aging (NIA); American Urological Association; Urology Care Foundation; Claude D. Pepper Older Americans Independence Center (OAIC)
• Investigators: Principal Investigator: Iman M Al-Naggar, PhD, UConn Health

Study record dates

Study Major Dates

• Study Start (Actual): April 3, 2024
• Primary Completion (Actual): April 1, 2026
• Study Completion (Actual): April 1, 2026

Study Registration Dates

• First Submitted: April 1, 2024
• First Submitted That Met QC Criteria: April 1, 2024
• First Posted (Actual): April 8, 2024

Study Record Updates

• Last Update Posted (Actual): May 1, 2026
• Last Update Submitted That Met QC Criteria: April 27, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: aging; LUTS; metabolic syndrome; OAB; MitoQ; urgency; urinary urgency; geroscience; gerotherapeutics
• Additional Relevant MeSH Terms: Metabolic Diseases; Urological Manifestations; Glucose Metabolism Disorders; Insulin Resistance; Hyperinsulinism; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Metabolic Syndrome; Lower Urinary Tract Symptoms; mitoquinone
• Other Study ID Numbers: 24-066-2; P30AG067988 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All IPD that underlie results in a publication after de-identification.
• IPD Sharing Time Frame: IPD and supporting information will be available 3 months and ending 5 years following article publication.
• IPD Sharing Access Criteria: Anyone wishing to access the data may do so after signing a data access/data transfer agreement. Requests should be made by contacting Dr. Iman Al-Naggar at alnaggar@uchc.edu.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No